Revvity Inc

Análisis de la acción Revvity Inc (RVTY)

$152.640

-2.045 (-1.34%)Al cierre

Loading chart…
Máximo
155.500
Apertura
154.440
Precio medio ponderado por volumen
153.25
Volumen
1.34M
Capitalización
13.04B
Mínimo
151.610
Importe
204.79M
EV/EBITDA, TTM
20.86

Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.

www.revvity.com

Análisis de IA of Revvity Inc (RVTY)

Comprar

Revvity Inc is a good buy right now due to its strong recent performance, with a current price of $154.18 and a year-to-date change of +57.09%. The stock is also showing positive momentum with an RSI of 61.707, indicating it is not overbought yet. Additionally, the forward P/E ratio of 24.15 suggests reasonable valuation compared to its growth prospects, especially with a gross margin of 57.13% in the latest quarter. However, the main risk is its high P/E ratio of 70.98, which indicates that the stock may be overvalued if growth does not meet expectations.

Métricas de valoración

El PER previsto actual de Revvity Inc (RVTY) es 24.15, frente a su media de 5 años de 22.13.

PER previsto

Valor razonable
Media 5A P/E
22.13
P/E actual
24.15
Sobrevalorada
25.11
Infravalorada
19.14

EV/EBITDA previsto

Sobrevalorado
Media 5A EV/EBITDA
18.12
EV/EBITDA actual
20.86
Sobrevalorada
20.57
Infravalorada
15.67

Precio/ventas previsto

Sobrevalorado
Media 5A P/S
4.58
P/S actual
5.64
Sobrevalorada
5.29
Infravalorada
3.87

Escenarios de precio de Alphio AI para RVTY

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%RVTY

$80.72

Precio del escenario

B

Base

Base · 50%RVTY

$80.47

Precio del escenario

B

Bajista

Bajista · 25%RVTY

$65.23

Precio del escenario

Ballenas con RVTY en cartera

C

Campbell & Company, LP

+ Con en carteraRVTY

+9.49%

Rentabilidad a 3 meses

E

EdgePoint Investment Group Inc.

+ Con en carteraRVTY

+3.94%

Rentabilidad a 3 meses

M

Meridiem Capital Partners LP

+ Con en carteraRVTY

+3.28%

Rentabilidad a 3 meses

V

Vaughan Nelson Investment Management, L.P.

+ Con en carteraRVTY

+1.31%

Rentabilidad a 3 meses

P

Port Capital LLC

+ Con en carteraRVTY

-1.25%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-24 (ET)

10:00:00

Everpure Stock Rises $20.86 to $130.51

08:30:00

Revvity Launches GSP T1D 3plex Detection Kit

2026-09-15 (ET)

10:00:00

Skyworks and Others See Notable Stock Gains

2026-09-09 (ET)

06:30:00

Revvity Acquires French Biotech Company HCD

2026-08-04 (ET)

06:30:00

FY26 Revenue Outlook Raised to $2.83B-$2.86B

Noticias

Preguntas frecuentes sobre RVTY, respondidas por Alphio AI

Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Revvity Inc is a good buy right now due to its strong recent performance, with a current price of $154.18 and a year-to-date change of +57.09%. The stock is also showing positive momentum with an RSI of 61.707, indicating it is not overbought yet. Additionally, the forward P/E ratio of 24.15 suggests reasonable valuation compared to its growth prospects, especially with a gross margin of 57.13% in the latest quarter. However, the main risk is its high P/E ratio of 70.98, which indicates that the stock may be overvalued if growth does not meet expectations.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar